Inflammatory rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus represent chronic inflammatory disorders that are caused by dysregulation of innate and adaptive immune responses. Here we review current advances in our understanding of the molecular underpinnings of these diseases and discuss consequences with respect to emerging targets and treatment strategies, which are increasingly enabling more robust disease control and the first prospects of a cure for previously chronic inflammatory rheumatic diseases.
Related products
| Catalog No. | Product Name | Description | Target |
|---|---|---|---|
| HV212016 | Anti-Human BAFF/BLyS/TNFSF13B Reference Antibody (Belimumab | Belimumab (HV212016) is a research-grade recombinant antibody targeting CD257. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns. | BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor |
Quick access
Contact Us
+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский